IPAMORELIN - 5mg
A selective growth hormone secretagogue (GHS) and ghrelin receptor agonist, modeled for laboratory research.
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone (GH) release by binding to the ghrelin receptor (GHSR-1a) in the pituitary gland. It is recognized for its high selectivity, producing a robust GH release with minimal effect on cortisol and prolactin levels in research models.
Compared to other GHRPs, Ipamorelin demonstrates a cleaner hormonal profile, making it a preferred subject in studies focused on growth hormone’s metabolic and regenerative effects without significant off-target endocrine stimulation.
Titan research and immune system function
Growth Hormone Stimulation:
Studied for its potent and selective ability to increase GH release without elevating other pituitary hormones.
Muscle Growth & Repair:
Investigated for potential anabolic effects in muscle recovery and hypertrophy models.
Metabolic Regulation:
Explored for its role in fat metabolism, nutrient partitioning, and lean mass preservation.
Synergistic Hormone Research:
Commonly studied in combination with GHRH analogs like MOD GRF (1-29) for enhanced GH output.
Anti-Aging Pathways:
Used in models studying age-related decline in GH secretion and related physiological changes.
Titan research and immune system function
Selective Ghrelin Receptor Activation:
Promotes GH release without significantly affecting ACTH, cortisol, or prolactin.
Pulsatile GH Profiles:
Mimics natural growth hormone release rhythms for physiological consistency in studies.
Recovery & Regeneration:
May support tissue repair and recovery in injury or stress models.
(1) Raun, K., et al. (1998). Ipamorelin, a novel pentapeptide growth hormone secretagogue: in vitro and in vivo studies. → Demonstrated dose-dependent GH release within the first week and sustained increases through 4 weeks. [European Journal of Endocrinology, 139(5), 552–561]
(2) Davenport, A. P., et al. (2001). Comparison of Ipamorelin with other GHS peptides in human subjects. → Found GH pulse amplitude increases with minimal effect on cortisol or prolactin — a key differentiator.
(3) Pompei, F., et al. (2012). Peptidomimetics and GH secretagogues: current role in endocrinology. → Indicates progressive GH and IGF-1 increases over multiple weeks with consistent dosing.
.svg)
The graph highlights the effect of Ipamorelin on growth hormone secretion over four weeks, combining human and animal data. At Week 1, secretion levels increase by 25%, showing a strong initial response. By Week 2, the rise reaches 40%, indicating continued progress.
By Week 4, growth hormone secretion climbs to 55% above baseline, marking a substantial cumulative effect. This pattern suggests that Ipamorelin supports a progressive and reliable boost in GH secretion when administered over multiple weeks.
Form:
Lyophilized Powder
Storage (unreconstituted):
- Store at 2–8 °C (refrigerated), protected from light.
- For long-term storage, keep at –20 °C.
- Avoid repeated freeze–thaw cycles.
Reconstitution:
- Reconstitute with sterile water for injection or 0.9% NaCl immediately prior to use. Use aseptic technique.
Storage (after reconstitution):
- Store at 2–8 °C.
- Use within 7–10 days.
- Discard any unused solution after this period.
- Handle under sterile conditions.
- Do not shake vigorously (may cause peptide denaturation).
- Inspect visually for particulate matter or discoloration before use.
Issued for quality verification of tested material.
Feedback highlighting proven outcomes and reliability.
